In my simplistic opinion NEU is a relatively short term play in the indicative efficacy of Trofinetide in the upcoming Phase II trial results. Success in this respect in one or more (of the three in progress) will see this multi-bag, to explode, the current SP, thus opening the door to NEU becoming an Australian icon company for years to come. Pedestrian (i.e. safety only) to substantively non-efficacious results in all trials will see NEU struggle on for years trying to make a go of its current Phase II Retts success. At this stage it is a pure risk/reward gamble - a chance to shoot for the stars or endure the usual slow painful death of the typical Aussie biotech speccy.
NEU Price at posting:
8.4¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)